#14293 -- Relief to Promote Domestic Production of Critical Medicines (of May 5, 2025, Regulatory)

Executive Order

Highlights

Fast-tracks domestic pharma plants.

Key Compliance/Risk Cue

FDA will ramp up inspections of foreign manufacturing facilities mandated to supply U.S. markets. Tariffs could significantly increase pricing on imported drugs.

Litigation Snapshot

No known lawsuits directly challenging EO 14293

URLs

https://www.federalregister.gov/documents/2025/05/08/2025-08267/regulatory-relief-to-promote-domestic-production-of-critical-medicines